A cold cap (scalp cooling) chills the scalp before, during and after each chemotherapy infusion so less of the drug reaches the hair follicles. In the two US trials that led to wider use, about half to two-thirds of women who cooled kept at least half of their hair, while no one in the comparison groups did. How well it works depends heavily on which chemotherapy you get.
How scalp cooling works
Hair follicles are among the fastest-dividing cells in the body, which is why many chemotherapy drugs hit them hard. Cooling the scalp narrows its blood vessels, so less drug reaches the follicles during the hours when blood levels peak, and the cold also slows follicle cell activity (Mayo Clinic). There are two broad kinds: machine-based systems that pump coolant through a fitted cap at a set temperature, and manual frozen caps that are swapped out as they warm.
Timing matters. In one of the pivotal studies, cooling started 30 minutes before each infusion, the scalp was held at about 3°C (37°F) throughout, and cooling continued for 90 to 120 minutes after the infusion ended (Rugo et al., JAMA 2017). That adds several hours to each treatment day.
The two trials, side by side
Both studies were published in JAMA in February 2017, both enrolled women with early-stage breast cancer, and both used a similar success bar: losing less than half of your hair. That point is worth stressing. "Success" did not mean keeping all your hair; it meant thinning that most people could manage without a wig.
| SCALP trial (Nangia et al.) | Cohort study (Rugo et al.) | |
|---|---|---|
| Design | Randomized, 7 US sites, stopped early for benefit at a planned interim analysis | Prospective cohort with a small matched control group, not randomized |
| Patients analyzed | 142 (95 cooled, 47 not) | 117 (101 cooled, 16 not) |
| Chemotherapy | About two-thirds taxane-based, one-third anthracycline-based | No anthracyclines in the cooled group; mostly docetaxel plus cyclophosphamide |
| How hair was judged | Clinician grading after 4 cycles | Patient self-assessment from photos, 4 weeks after the last cycle |
| Result with cooling | 50.5% kept at least half their hair | 66.3% lost half or less |
| Result without cooling | 0% | 0% |
Sources: Nangia et al., JAMA 2017; Rugo et al., JAMA 2017.
What these studies did not show
- Blinding was not possible. Patients and staff knew who was cooling, and the Rugo study relied on patients rating their own photos (a blinded panel also scored them).
- Small control groups. The Rugo cohort had only 16 comparison patients, and the SCALP trial stopped early, which makes estimates less precise.
- Industry funding. Each study was sponsored by the maker of the device it tested.
- Big differences between sites. In the SCALP trial, success varied widely from one center to another.
- Mostly one cancer type. Nearly all the strong evidence comes from breast cancer.
Your chemotherapy regimen changes the odds
This is the part most cold cap guides gloss over. Scalp cooling tends to work best with taxane-based chemotherapy given on its own and less well with anthracycline-based regimens (such as doxorubicin plus cyclophosphamide). In the Rugo study, which excluded anthracyclines, success was 60.5% with docetaxel plus cyclophosphamide but 83.3% with weekly paclitaxel and 83.3% with docetaxel plus carboplatin, though those last two groups had only 12 patients each.
A 2024 review of docetaxel and hair loss pulled the wider literature together: scalp cooling prevented significant loss in roughly 95 to 100% of patients on paclitaxel regimens, compared with a much wider 43 to 96% on docetaxel regimens (Perez et al., Current Oncology 2024). Higher doses, combinations and longer infusions generally make cooling harder. So the most useful question for your oncology team is not "Do cold caps work?" but "How likely are they to work with my specific regimen and dose?"
Permanent hair loss after chemotherapy
Most chemotherapy hair loss is temporary: hair usually starts falling within weeks of the first treatment and often regrows within about six months after chemotherapy ends. Doctors call it persistent (or permanent) chemotherapy-induced alopecia when hair has not fully grown back six months after the last dose (Perez et al., 2024).
Docetaxel stands out here. In a retrospective UK study cited in that review, persistent hair loss was reported in 23.3% of patients treated with docetaxel versus 10.1% with paclitaxel. Treatment results for persistent loss are, in the review's words, "mostly disappointing," which is one reason prevention gets so much attention. Scalp cooling is, as of November 2026, the only FDA-cleared method for preventing chemotherapy hair loss, with the first system cleared in 2015. Whether it reliably prevents the persistent form is still being studied.
Is it safe?
Side effects are mostly about the cold: headaches, scalp pain, and chills (Mayo Clinic). In the Rugo study, 3.8% had mild headaches and 2.8% stopped because they felt too cold.
The scalp metastasis question. A long-standing worry is that cooling could shield stray cancer cells in the scalp from chemotherapy. A meta-analysis summarized in the 2024 review found scalp metastases in 0.67% of patients who cooled and 0.4% of those who did not, a difference that was not statistically significant. That is reassuring for solid tumors such as breast cancer, but it is the reason cooling is generally not offered for blood cancers like leukemia, where cancer cells circulate throughout the body, and is not recommended for some other cancer types (Mayo Clinic). Your oncologist makes this call.
Practical points before you start
- Ask early. Cooling has to begin with the first infusion to give the best chance, so raise it when your treatment plan is being set.
- Check coverage. Mayo Clinic notes that Medicare began covering certain scalp cooling devices in 2022 and many insurers reimburse, but not every system is covered. Ask your insurer and cancer center for written details.
- Fit is everything. A snug cap with good scalp contact matters. Thick hair can insulate the scalp, and tightly curled or coily hair may need to be worn in small braids or otherwise prepared so the cap sits close.
- Be gentle between sessions. Cancer centers commonly advise less frequent washing, lukewarm water, mild shampoo, and avoiding heat styling, tight hairstyles and chemical treatments during chemo. Our hair care tips for thinning hair cover the basics.
- Have a backup plan. Even with good results, many people see noticeable shedding. Concealers, scarves or a wig can bridge the gap.
After chemotherapy: helping regrowth
Topical minoxidil is widely used after chemotherapy to support regrowth, including for persistent loss, and low-dose oral minoxidil is being studied for this use (Perez et al., 2024). Evidence for regrowth after chemo is limited, and timing should be agreed with your oncologist. Some people on long-term hormone-blocking breast cancer therapy notice ongoing thinning that looks like female pattern hair loss, which a dermatologist can assess separately. For more on how minoxidil works, see our minoxidil pharmacology guide.
FAQ
Does a cold cap stop all hair loss during chemo?
No. In the main trials, success meant losing less than half of your hair. Most people who cool still notice some shedding and thinning.
Can I use scalp cooling with any type of cancer?
Not always. Most evidence is in breast cancer and other solid tumors. It is generally not used for blood cancers such as leukemia. Your oncologist decides whether it is appropriate.
Is hair loss after chemo the same as telogen effluvium?
Not quite. Chemotherapy mainly damages actively growing hairs, so loss can be fast and heavy. Telogen effluvium is a delayed shedding after a shock to the body and can also follow illness or surgery during cancer care.
Have a question about your own situation? Ask us, or browse more research in Hairloss Labs.